Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1385077 | 0.90 | TPSAB1 (1.00) | TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL4412972 | 0.89 | TPSAB1 (1.00) | TPSAB1 | |
| SCHEMBL4414708 | 0.83 | TPSAB1 (1.00) | TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL4397995 | 0.81 | TPSAB1 (0.69) | TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL4410347 | 0.80 | TPSAB1 (1.00) | TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL4395988 | 0.79 | TPSAB1 (0.79) | TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL4410596 | 0.78 | TPSAB1 (0.65) | TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL4407730 | 0.78 | TPSAB1 (0.65) | TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL4398468 | 0.76 | TPSAB1 (0.63) | TPSAB1 | |
| Trifluoroacetic Acid SCHEMBL4399080 | 0.76 | TPSAB1 (0.62) | TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | TPSAB1 4/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | TPSAB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.